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Abstract
Background: Genome sequencing and bioinformatics have provided the full hypothetical proteome of many pathogenic
organisms. Advances in microarray and mass spectrometry have also yielded large output datasets of possible target
proteins/genes. However, the challenge remains to identify new targets for drug discovery from this wealth of information.
Further analysis includes bioinformatics and/or molecular biology tools to validate the findings. This is time consuming and
expensive, and could fail to yield novel drugs if protein purification and crystallography is impossible. To pre-empt this, a
researcher may want to rapidly filter the output datasets for proteins that show good homology to proteins that have
already been structurally characterised or proteins that are already targets for known drugs. Critically, those researchers
developing novel antibiotics need to select out the proteins that show close homology to any human proteins, as future
inhibitors are likely to cross-react with the host protein, causing off-target toxicity effects later in clinical trials.
Methodology/Principal Findings: To solve many of these issues, we have developed a free online resource called
Genomes2Drugs which ranks sequences to identify proteins that are (i) homologous to previously crystallized proteins or (ii)
targets of known drugs, but are (iii) not homologous to human proteins. When tested using the Plasmodium falciparum
malarial genome the program correctly enriched the ranked list of proteins with known drug target proteins.
Conclusions/Significance: Genomes2Drugs rapidly identifies proteins that are likely to succeed in drug discovery pipelines.
This free online resource helps in the identification of potential drug targets. Importantly, the program further highlights
proteins that are likely to be inhibited by FDA-approved drugs. These drugs can then be rapidly moved into Phase IV clinical
studies under ‘change-of-application’ patents.
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Introduction
The modern molecular biologist is confronted with increasingly
large datasets. Genome sequencing data, proteomics data and
microarray data are increasingly accessible, but difficult and
laborious to interpret. Considering the investment cost of target
validation, one needs to rank genome-sized output data in favour
of proteins that can readily be modelled using homology
modelling, as these structural models can be used in virtual high
throughput screening (vHTS) of large compound libraries [1–3].
Microbiologists designing antibiotics need to rank their candidate
proteins for lack of similarity with any human protein, to reduce
the possibility of potentially toxic off-target side effects due to
cross-reactivity between inhibitors and patient host proteins. In
addition, it is now possible to screen the proteome for homology to
targets of known drugs, using the DrugBank dataset [4], and
propose FDA-approved drugs for rapid development to Phase IV
clinical trials as these compounds are all defined as safe for human
consumption. Much of the necessary search functionality is
already available online [4–7]. However, the assimilation of this
data into a cohesive table for analysis is non-trivial for molecular
biologists unskilled in programming languages or database
management. By providing a convenient online interface and
summary table output, we hope to make this analysis open to a
wide research audience.
Materials and Methods
Genomes2Drugs was developed using open source Java
Enterprise Edition in the NetBeans IDE 6.0 programming
environment and deployed on Sun Application Server [8]. The
Basic Local Alignment Search Tool (BLAST) program 2.2 was
obtained from the USA National Center for Biotechnology
Information (NCBI). The human genome protein sequences and
PDB protein sequences were also obtained from NCBI. Drug
target protein sequences were obtained from the University of
Alberta DrugBank website [4]. Output data files are parsed using
BioJava 1.6 and the data entered into an open source MySQL 5.1
database. The test genome Plasmodium falciparum 3D7 protein
sequences were obtained from the European Molecular Biology
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Laboratory - European Bioinformatics Institute (EMBL-EBI)
Integr8 website (493.P_falciparum, [9]).
Results
Genomes2Drugs is a freely available web-based search engine
that simultaneously searches each input protein sequence against
the protein sequences of the human genome, the DrugBank
dataset drug targets and the PDB protein structure database
[http://mmg.rcsi.ie:8080/g2d/]. The schema for information
processing is shown in Figure 1. Users can input either a single
FASTA formatted protein sequence [10] or multiple sequences,
either in an input box or an uploaded text file. For instance,
complete proteome sequences can be downloaded from the
EMBL-EBI Integr8 website [9], and uploaded into Genomes2-
Drugs. Screen shots of the input and output screens are shown in
supplementary Figure S1 online. Users need to register and submit
an email address, as processing occurs in the background. User
information will remain private and will not be given to any third
party. The user will be emailed when the job is complete, and can
then login to download the result XML file which can be imported
into Microsoft Excel as a ‘As an XML list’, provided the user has
downloaded the ‘g2d.xsd’ file (available online) into the same
directory. The results from a few input polypeptides can be opened
Figure 1. Schema of data processing. Genomes2Drugs is a free online resource. The web interface was written using open-source Java Enterprise
Edition, BioJava 1.6 and NetBeans IDE 6.0. Input sequences are aligned against the human proteome, the PDB dataset and the DrugBank target
proteins dataset. Only the best results are preserved. The resulting output files are parsed using BioJava and entered into a MySQL 5.1 database,
where the results are sorted and ranked. Output XML files are generated from this data.
doi:10.1371/journal.pone.0006195.g001
Genomes2Drugs
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in Excel, while larger genome wide searches should be opened in a
database viewer like Microsoft Access, for which a viewing form is
included (see supplementary Figure S1B). For easy of access to the
data in Access we have included a template MDB file and XSD
schema file which need to be downloaded to the same directory as
the XML file. The output terms are described in Table 1. Each
EBLASTp value is derived from the optimal alignment across the
genome using default settings of NCBI’s freely available BLASTp
algorithm [5,6]. As the best alignment score is recorded for each
input protein, it follows that a poor score indicates that there is no
matching protein in the comparator set. Thus a large EBLASTp[-
query vs human genome] value indicates that there is likely no
match for that query protein in the human genome. Similarly,
good sequence identity, with a small EBLASTp[query vs PDB] value
indicates that the query sequence has a close homologue in the
PDB structural database. No lower limit is set for any E value
during the alignment calculation and only the best results are
shown.
The Æhuman expectæ and ÆPDB expectæ columns can be used
individually to rank the whole input genome for proteins showing
little homology to the human genome or good homology to a
protein for which the crystal structure has been determined,
respectively. More conveniently, the ratio of these expect values
can be used to rank the output list according to proteins that would
be readily structurally modelled, while also showing little identity
to any human proteins. This ratio is provided in the logarithmic
(base 10) form, in the column RhuPDB (2), which has been ranked
by descending value.
Table 1. Key for output file column headings.
Column title Explanation
query_id Unique query entry number.
query_accession First word of input protein title.
query_title Input protein title after ‘æ’.
query_length Number of residues in input sequence.
RhuDB Logarithm (base 10) of the ratio of Æhuman expectæ and Ædrugbank expectæ.
RhuDBRank Entries ranked by descending RhuDB.
RhuPDB Logarithm (base 10) of the ratio of Æhuman expectæ and ÆPDB expectæ.
RhuPDBRank Entries ranked by descending RhuPDB.
RDBPDB Logarithm (base 10) of the ratio of Ædrugbank expectæ and ÆPDB expectæ.
RDBPDBRank Entries ranked by descending RDBPDB.
human_accession First word of human protein title.
human_title Extracted from target sequence name in BLASTp output.
human_expect Only optimal human/query alignment is returned, i.e. lowest BLASTp E value.
human_rank Query vs Human genome alignments are ranked by descending Æhuman_expectæ. I.e. poor/no match to the human genome is
scored well and given a low rank number.
human_identities Number of identical residues in query and human sequences.
human_percent_identities (Æhuman identitiesæ/Æquery lengthæ)*100.
human_positives Number of homologous residues in query and human sequences.
human_percent_positives (Æhuman positivesæ/Æquery lengthæ)*100.
pdb_accession Protein Data Bank accession number: pdbxxxxx
pdb_title Name of protein 3-D structure.
pdb_expect Only optimal PDB/query alignment is returned, i.e. lowest BLASTp E value.
pdb_rank Query vs Protein Data Bank sequence alignments are ranked by ascending Æpdb_expectæ. I.e. excellent matches with very low E
values are scored well and given a low rank number.
pdb_identities Number of identical residues in query and PDB sequences.
pdb_percent_identities (Æpdb_identitiesæ/Æquery lengthæ)*100.
pdb_positives Number of homologous residues in query and PDB sequences.
pdb_percent_positives (Æpdb_positivesæ/Æquery lengthæ)*100.
drugbank_accession DrugBank accession number of target protein: nnnn_all_target_protein.fasta.
drugbank_title Name of DrugBank target protein, including target drug accession numbers in parentheses: (DBnnnnn).
drugbank_expect Only optimal DrugBank/query alignment is returned, i.e. lowest BLASTp E value.
drugbank_rank Query vs DrugBank sequence alignments are ranked by ascending Æpdb_expectæ. I.e. excellent matches with very low E values are
scored well and given a low rank number.
drugbank_identities Number of identical residues in query and DrugBank sequences.
drugbank_percent_identities (Ædrugbank_identitiesæ/Æquery lengthæ)*100.
drugbank_positives Number of homologous residues in query and DrugBank sequences.
drugbank_percent_positives (Ædrugbank_positivesæ/Æquery lengthæ)*100.
doi:10.1371/journal.pone.0006195.t001
Genomes2Drugs
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The ratio values are calculated as follows:
RhuDB~log10
EBLASTp query vs human genome½ 
EBLASTp query vsDrugBank½ 
 
ð1Þ
RhuPDB~log10
EBLASTp query vs human genome½ 
EBLASTp query vs PDB½ 
 
ð2Þ
RhuDBPDB~log10
EBLASTp query vsDrugBank½ 
EBLASTp query vs PDB½ 
 
ð3Þ
Where EBLASTp[] is the expect value extracted from the BLASTp
alignment output file using open-source BioJava [8]. The
BLASTp algorithm approximates the best alignment (E value
= 1e-180) to zero. To include these data in the ratios, we set
E= 0.0 back to E= 1e-180. To include the important ‘NULL’
results from the human search in our ratio calculations, we
arbitrarily set this to 1000. The full range for the RhuDB and
RhuPDB values is thus 2183 to +183. However, a ‘NULL’ result
from the PDB and DrugBank database searches needs to be
flagged, as these query proteins are likely to be more difficult to
homology model, and do not show homology to targets of known
drugs. Error messages from these ratios are defined in Table 2.
The negative numbers used will rank these queries to the bottom
a descending list.
Query sequences that show good homology to crystal structure
template sequences, but poor/no homology to any protein within
the human genome, will have high RhuPDB values. The researcher
may be particularly interested in the ‘‘hypothetical’’ or ‘‘unknown’’
query proteins that are ranked well according to RhuPDB (in the top
,100) as these may make excellent targets for novel research into
characterisation, validation, crystallography/modelling and virtual
high throughput screening.
Table 2. Definition of ratio ranges and error codes.
RhuDB RhuPDB RDBPDB
EBLASTp[hum]y vs. EBLASTp[DB/PDB]
j 2183 to 183 2183 to 183 27000
EBLASTp[hum]
y vs. ‘Null’ DB/PDBQ 22000 25000 28000
‘Null’ DB/PDBQ vs. EBLASTp[hum]
y 23000 26000 29000
yBLASTp expect value of the best query/human genome alignment (null = 1000).
jBLASTp expect value of the best query/DrugBank alignment or query/protein data bank alignment (not null).
QNo alignment found between query and either DrugBank or PDB databases (null).
doi:10.1371/journal.pone.0006195.t002
Figure 2. Enrichment of P. falciparum proteome by RhuPDB – PDB targets. Enrichment curves plot the accumulation of user-defined ‘hits’ as a
function of rank number. Thus in an ideal case (red line), each consecutive entry in the ascending ranked list will be a hit. Alternatively, if ranking
provides no selection the hits will be distributed randomly across the genome (light blue line). The enrichment percentage as a function of rank are
shown in dark blue. The 5283 proteins in the P. falciparum 3D7 strain test set were searched using Genomes2Drugs and ranked by RhuPDB. P.
falciparum and malaria related hits from PDB were identified using keyword searching of the Æpdb_titleæ field, and their position in the ranked list
identified. The insert, which highlights the first 500 entries, shows that almost 80% of the entries with close homology to known P. falciparum crystal
structures were identified in the first 10% of the genome.
doi:10.1371/journal.pone.0006195.g002
Genomes2Drugs
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A sample output from a search using the full proteome of the
malaria parasite, Plasmodium falciparum, is shown in supplementary
Table S1 online. The 5283 FASTA formatted protein sequences in
the malarial genome were downloaded from the EMBL-EBI
Interg8 website [9] and used as a test set. Of the top 50 entries as
ranked by RhuPDB, the majority (68%) showed previous investi-
gation and/or homology to crystal structures of Plasmodium
falciparum proteins, indicating that this simple ranking system
highlights good candidate drug targets (see Figure 2). This is
further illustrated over the full genome test set in Figure 2. A query
entry was defined as a ‘hit’ if the PDB title contained keywords
associated with malaria. After ranking all 5283 test set entries
according to RhuPDB, the percentage of hits found is plotted as a
function of rank number. Thus in the insert in Figure 2 it is clear
that ,80% of the hits are recovered within the first 500 entries, or
10% of the genome. The red line in Figure 2 shows an ideal case
where each consecutive entry is a hit, while the light blue line
shows a random distribution of hits. Interestingly, 25 of the top 50
entries are uncharacterised ‘‘hypothetical’’, ‘‘putative’’ or ‘‘un-
known’’ proteins, which warrant further investigation as novel
drug targets by virtue of the fact that they are (i) pathogen specific
and (ii) similar to a structural template for homology modelling.
Similarly, query sequences homologous to known drug targets,
as defined by DrugBank [4], but showing poor/no homology to
any human protein, will have high RhuDB values. In Figure 3, the
full P. falciparum proteome test set was ranked according to RhuDB
and hits identified as having malaria related keywords in the best
PDB match title, again indicating that high ranking entries are
likely to be well characterised targets for drug discovery and
development. Importantly, the same ranking showed good
enrichment of known antimalarial drugs, as defined by DrugBank
(Figure 4, see listed in supplementary Table S2 online). The
DrugBank hits for each query sequence are listed at the bottom of
the Microsoft Access form supplied in the output of Genomes2-
Drugs (see supplementary Figure S1B). These compounds include
experimental small molecule drugs as well as FDA (Food and Drug
Administration) approved medicinal drugs, which can be pur-
chased and tested for in vitro effectivity [4]. After ranking the P.
falciparum test set by RhuPDB, 8 of the top 50 proteins showed
homology to targets of FDA approved drugs. If an FDA approved
drug is found to be effective against the pathogen of interest, a
‘change-of-application’ patent could be sought. As all the
necessary toxicology, pharmacology and dosing analysis has
already been completed, Phase IV clinical trials to confirm
therapeutic use may be more rapidly instigated. This could
become an extremely efficient and rapid route for drug
development. With a lower financial barrier to entry, this strategy
could be especially important in the development of therapeutic
drugs against neglected infectious diseases affecting the developing
world.
Discussion
We have developed a free online resource that enriches any
sized dataset of proteins of interest for those proteins likely to be
most usefully in further drug discovery efforts. The program
addresses the need to focus drug discovery effort on those protein
targets that (i) do not show homology to proteins in the human
genomes and (ii) show close homology to proteins for which the 3-
dimentional structure is known. As an added feature, each input
protein sequence is compared to the DrugBank set of known drug
targets, and may identify known drugs that are able to inhibit the
protein under investigation.
Figure 3. Enrichment of P. falciparum proteome by RhuDB – PDB targets. Enrichment curves were plotted as described in Figure 2. The 5283
protein malarial proteome was ranked by RhuDB. P. falciparum and malaria related hits from PDB were identified using keyword searching of the
Æpdb_titleæ field. The enrichment percentage as a function of rank are shown in dark blue, while the red line shows an ideal case, and the light blue
line indicates a random distribution. The insert highlights the first 500 entries.
doi:10.1371/journal.pone.0006195.g003
Genomes2Drugs
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Supporting Information
Figure S1 Screen shots of the input and output of the online
Genomes2Drugs tool.
Found at: doi:10.1371/journal.pone.0006195.s001 (0.58 MB
PDF)
Table S1 Genomes2Drugs search of the Plasmodium falciparum
proteome. The FASTA formatted proteome of the malarial
parasite P. falciparum strain 3D7 was downloaded from EMBL-
EBI Interg8. The Genomes2Drugs output was sorted by RhuPDB.
Numerous fields have been removed and abridged for clarity.
Putative, uncharacterised proteins likely to be good targets for
further analysis are highlighted in blue. PDB homologue titles
containing the word ‘plasmodium’ are highlighted in yellow.
DrugBank hits associated with malaria, according to NCBI
PubMed, are highlighted in green.
Found at: doi:10.1371/journal.pone.0006195.s002 (0.05 MB
PDF)
Table S2 DrugBank DrugCards with keywords ‘‘plasmodium’’
or ‘‘malaria’’.
Found at: doi:10.1371/journal.pone.0006195.s003 (0.01 MB
PDF)
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